Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

E-cigarettes, nicotine pouches, and heated tobacco hurt blood vessels, increase heart disease risk. All nicotine products ...

The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.

Pharma marketers enter 2026 asking where DTC fits in the DTP era.  | Pharma marketers enter 2026 asking where DTC fits in the ...

AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

Informing patients about bariatric surgery is a comprehensive discussion, so aim to provide the most up-to-date information about both pre- and post-surgery expectations.

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...

Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company ...

FDA and European regulators have received tens of thousands of adverse event reports, including seizures and deaths, ...